Tvardi Therapeutics (TVRD) Income towards Parent Company: 2013-2017
Historic Income towards Parent Company for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$12.4 million.
- Tvardi Therapeutics' Income towards Parent Company fell 7.81% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.01%. This contributed to the annual value of -$57.3 million for FY2016, which is 132.00% down from last year.
- Latest data reveals that Tvardi Therapeutics reported Income towards Parent Company of -$12.4 million as of Q3 2017, which was down 33.81% from -$9.3 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' Income towards Parent Company registered a high of $5.3 million during Q2 2013, and its lowest value of -$22.2 million during Q1 2017.
- Over the past 3 years, Tvardi Therapeutics' median Income towards Parent Company value was -$10.7 million (recorded in 2016), while the average stood at -$11.4 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first slumped by 168.30% in 2014, then grew by 28.87% in 2017.
- Tvardi Therapeutics' Income towards Parent Company (Quarterly) stood at -$2.1 million in 2013, then slumped by 99.33% to -$4.2 million in 2014, then crashed by 128.43% to -$9.5 million in 2015, then crashed by 130.56% to -$22.0 million in 2016, then decreased by 7.81% to -$12.4 million in 2017.
- Its last three reported values are -$12.4 million in Q3 2017, -$9.3 million for Q2 2017, and -$22.2 million during Q1 2017.